Effect of Schisandra Fruit on Neurochemicals in Hippocampus of Diabetic Encephalopathy Rat Using Online MD-HPLC-MS/MS†

doi:10.7503/cjcu20140813

Abstract

Abstract:

The results of morris water maze test showed that the extract of schisandra fruit could significantly shorten the escape latency time(ELT) and increase the time of crossing target zone and central zone(%) of diabetic encephalopathy rats. In order to investigate the mechanism of schisandra fruit on the improving ability of learning and memory, online MD-HPLC-MS/MS method was applied to explore the effect of schisandra fruit on eight neurochemicals changes in hippocampus of diabetic encephalopathy rats. The results showed that the contents of Glu, Ser, DA and 5-HT decreased significantly(P<0.05), while the contents of Tau and Ach increased significantly(P<0.01) after treated by schisandra fruit. The contents of Asp and GABA tended to decrease but the difference was not significant(P>0.05). The levels of eight neurochemicals regulated to normal level. The results indicated that schisandra may play a protective function of the central nervous system by adjusting the contents of neurochemicals in diabetic rats, which can improve the memory and learn ability of diabetic encephalopathy rat.

Key words: Schisandra fruit, Online MD-HPLC-MS/MS, Diabetic encephalopathy rat, Hippocampus, Neurochemical

CLC Number:

O656

TrendMD:

PI Zifeng, WANG Qianqian, ZHANG Jing, Song Fengrui, LIU Zhiqiang. Effect of Schisandra Fruit on Neurochemicals in Hippocampus of Diabetic Encephalopathy Rat Using Online MD-HPLC-MS/MS^†[J]. Chem. J. Chinese Universities, 2015, 36(3): 442.

Figures/Tables 6

References 33

[1]	Editorial Committee of Pharmacopoeia of People’s Republicof China, Pharmacopoeia of People’s Republic of China, Beijing, 2010, 61—62
	(中华人民共和国药典委员会, 中华人民共和国药典, 北京, 2010, 61—62)
[2]	Lu H., Liu G. T., Planta Med., 1992, 58, 311—313
[3]	Hu Y. W., Food and Drug, 2008, 10(11), 53—54
	(胡彦武. 食品与药品, 2008, 10(11), 53—54)
[4]	Huyke C., Engel K., Simon-Haarhaus B., Quirin K. W., Schempp C. M., Planta Med., 2007, 73, 1116—1126
[5]	Wang Y. C., Ren K., Fan H. Y., Shen N., Huang X. D., Chang Y., Xu N., Liu S. B., Liu W., Lei J. T., An Y., Chen X., Chin. J. Chin. Mater. Med., 2011, 36(23), 3310—3314
	(王艳春, 任旷, 范红艳, 沈楠, 黄晓东, 常影, 许娜, 刘师兵, 刘微, 雷钧涛, 安英, 陈雪. 中国中药杂志, 2011, 36(23), 3310—3314)
[6]	Yu F., Tuo X. P., Lü J. Y., Chen H. S., Acad. J. Sec. Mil. Med. Univ., 2007, 28(12), 1351—1355
	(于方, 拓西平,吕建勇, 陈海生. 第二军医大学学报, 2007, 28(12), 1351—1355)
[7]	Gao W. R., Jin X. Z., Li X. D., Lishizhen Med. Mater. Med. Res., 2010, 21(10), 2705—2706
	(高文荣, 金香子, 李香丹. 时珍国医国药, 2010, 21(10), 2705—2706)
[8]	Wang Y. C., Ren K., Fan H. Y., Shen N., Huang X. D., Xu N., Liu S. B., Liu W., Lei J. T., An Y., Chen X., Chang Y., Chin. Pharm. J., 2011, 46(11), 1097—1103
	(王艳春, 任旷, 范红艳, 沈楠, 黄晓东, 许娜, 刘师兵, 刘微, 雷钧涛, 安英, 陈雪, 常影. 中国药学杂志, 2011, 46(11), 1097—1103)
[9]	Zhang J.F., Coupling on-line Microdialysis Sampling with the Electrogenerated Chemiluminescence Sensor for Studying Drug Protein Interactions, Shanxi Normal University, Xi’an, 2012
	(张建锋. 在线微透析电化学发光传感器研究药物蛋白相互作用, 西安: 陕西师范大学, 2012)
[10]	Chang L. W., Xu G. Y., Han H. W., Chang X. Y., Zhao Z., Chem. J. Chinese Universities,2002, 23(4), 552—554
	(常理文, 徐桂芸, 韩慧婉, 常溪燕, 赵卓. 高等学校化学学报, 2002, 23(4), 552—554)
[11]	Zheng H., Shi L. F., Hu J. H., Biomed. Chromatogr., 2007, 21(1), 101—106
[12]	Tzschentke T. M., Folgering J. H. A., Flik G., de Vry J., Neurosic. Lett., 2012, 507(2), 151—155
[13]	Pan L. Y., Wang C. J., Yuan J. B., Zhang Y., Huang L. J., Wang Z. F., Chem. J. Chinese Universities,2014, 35(2), 237—243
	(潘丽英, 王承健, 袁江北, 张英, 黄琳娟, 王仲孚. 高等学校化学学报, 2014, 35(2), 237—243)
[14]	Ma Q. S., Wang Q., Zhao K. S., Zhai S. B., Liu S., Liu Z. Q., Chem. J. Chinese Universities,2013, 34(12), 2716—2720
	(马青山, 王茜, 赵凯姝, 翟淑波, 刘舒, 刘志强. 高等学校化学学报, 2013, 34(12), 2716—2720)
[15]	Xue C. F., Guo J. M., Qian D. W., Duan J. A., Shang E. X., Shu Y., Lu Y. W., J. Chromatogr. B,2011, 879, 317—325
[16]	Wang C., Li S., Tang Y. J., Wang S. W., Zhang Y. L., Fan G. R., Li L. Q., Zhang Y., J. Pharm. Biomed. Anal., 2012, 64/65, 1—7
[17]	Liu L., Huang J. Q., Li K. X., Hu X., Sun C. H., J. Chromatogr. B,2011, 879, 56—60
[18]	Wang Q. Q., Zhang J., Pi Z. F., Liu S., Song F. R., Liu Z. Q., Chin. J. Anal. Chem., 2014, 42(7), 997—1001
	(王倩倩, 张静, 皮子凤, 刘舒, 宋凤瑞, 刘志强. 分析化学, 2014, 42(7), 997—1001)
[19]	Das J., Roy A., Sil P. C., Food Funct., 2012, 3(12), 1251—1264)
[20]	Chen W. Z., Wang K. Y., Hong Z., Lü C. Z., Chinese J. Neuroanat., 2008, 24(4), 425—428
	(陈文珍, 王开颜, 洪震, 吕传真. 神经解剖学杂志, 2008, 24(4), 425—428)
[21]	Wang C. Y., Zhang W. Y., Song F. R., Liu Z. Q., Liu S. Y., Amino Acids,2012, 42, 1889—1895
[22]	Sun M., Zhao Y. M., Xu C., J. Apopl. Nervo. Dis., 2008, 25(5), 577—579
	(孙明, 赵育梅, 徐超. 中风与神经疾病杂志, 2008, 25(5), 577—579
[23]	Kim K. S., Oh D. H., Kim J. Y., Lee B. G., You J. S., Chang K. J., Chung H., Yoo M. C., Yang H. I., Kang J. H., Hwang Y. C., Ahn K. J., Chung H. Y., Jeong I. K., Exp. Mol. Med., 2012, 44(11), 665—673
[24]	O’Brein M. D., Dementia, 1994, 5, 133—136
[25]	Perry E., Walker M., Grace J., Perry R., Trend Neurosci., 1999, 22(6), 273—280
[26]	Wigstrom H., Gustafsson B., Nature,1983, 301, 603—604
[27]	Wang Z., Zhang L., Chin. J. Diabete,1999, 7(4), 219—221
	(王真, 张路. 中国糖尿病杂志, 1999, 7(4), 219—221)
[28]	He W. J., Ruan H. Z., Prog. Physiol. Sci., 2009, 40(4), 303—307
	(何文娟, 阮怀珍. 生理科学进展, 2009, 40(4), 303—307)
[29]	Ren T. J., Wang G. H., Jiang Z. L., Chin. J. Pathophys., 2012, 38(3), 470—477
	(任桃杰, 王国华, 姜正林.中国病理生理杂志, 2012, 38(3), 470—477)
[30]	Perez-Garcia G., Meneses A., Behav. Brain Res., 2009, 202, 102—113
[31]	Sarkisyan G., Hedlund P. B., Behav. Brain Res., 2009, 202, 26—31
[32]	Geng L., Liu D. S., Hao Y. Y., Guo R. C., Wang X. L., Zhang W. D., J. Shandong Univ.(Health Sciences), 2008, 46(7), 689—692
	(耿磊, 刘德山, 郝媛媛, 郭瑞臣, 王新陆, 张维东. 山东大学学报(医学版), 2008, 46(7), 689—692)
[33]	Luine V., Bowling D., Hearns M., Brain Res., 1990, 537, 271—278

Analyte	Cone voltage/V	Quantitation transition, m/z (Collision/eV)	Confirmation transition, m/z (Collision/eV)	t_R/min
Glutamic acid(Glu)	20	148.10>84.05(16)	148.03>102.01(10)	6.27
Aspartic acid(Asp)	22	134.01>73.92(14)	134.08>87.97(10)	6.07
γ-Aminobutyric acid(GABA)	20	104.04>87.05(10)	104.02>68.97(14)	5.70
Serine(Ser)	19	106.07>60.07(10)	105.99>87.94(14)	5.78
Taurine(Tau)	26	126.04>44.02(14)	126.03>108.08(10)	6.09
Acetylcholine(Ach)	18	146.01>87.03(14)	146.01>43.06(22)	9.99
Dopamine(DA)	18	154.18>136.97(10)	154.18>90.96(20)	10.49
5-Hydroxytryptamine (5-HT)	15	177.02>160.00(12)	177.02>132.00(20)	14.89

Analyte	Cone voltage/V	Quantitation transition, m/z (Collision/eV)	Confirmation transition, m/z (Collision/eV)	t_R/min
Glutamic acid(Glu)	20	148.10>84.05(16)	148.03>102.01(10)	6.27
Aspartic acid(Asp)	22	134.01>73.92(14)	134.08>87.97(10)	6.07
γ-Aminobutyric acid(GABA)	20	104.04>87.05(10)	104.02>68.97(14)	5.70
Serine(Ser)	19	106.07>60.07(10)	105.99>87.94(14)	5.78
Taurine(Tau)	26	126.04>44.02(14)	126.03>108.08(10)	6.09
Acetylcholine(Ach)	18	146.01>87.03(14)	146.01>43.06(22)	9.99
Dopamine(DA)	18	154.18>136.97(10)	154.18>90.96(20)	10.49
5-Hydroxytryptamine (5-HT)	15	177.02>160.00(12)	177.02>132.00(20)	14.89

Group	Dose/(g·kg^-1)	ELT/s	Central zone(%)	Times of crossing target zone
Control group		51.90±34.62^**	21.87±6.25^*	2.43±0.78^*
Model group		103.50±33.06	15.23±5.34	1.05±0.57
Schisandra group	2	51.53±47.80^**	24.70±5.97^**	3.50±0.84^**

Group	Dose/(g·kg^-1)	ELT/s	Central zone(%)	Times of crossing target zone
Control group		51.90±34.62^**	21.87±6.25^*	2.43±0.78^*
Model group		103.50±33.06	15.23±5.34	1.05±0.57
Schisandra group	2	51.53±47.80^**	24.70±5.97^**	3.50±0.84^**

Analyte	t_R/min	Dynamic range/(μmol·L^-1)	Regression equation	Correlation coefficient(R²)	LOQ/(nmol·L^-1)
Glu	6.28	0.25—10.0	y=13.2x+3025.2	0.999	50
Asp	6.10	0.1—5.0	y=16.1x+1886.3	0.999	80
GABA	5.72	0.1—2.5	y=4.56x+235.3	0.997	48
Tau	6.09	0.5—10.0	y=0.81x+323.7	0.998	250
Ser	5.79	0.5—10.0	y=7.34x+2247.2	0.999	75
Ach	9.99	2×10^-4—10×10^-2	y=775.0x+1102.2	0.995	0.02
DA	10.50	5×10^-4—10×10^-2	y=354.7x-0.4	0.997	0.025
5-HT	14.89	5×10^-4—10×10^-2	y=296.5x-7.1	0.999	0.075